A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis
Latest Information Update: 01 Dec 2023
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Bio-Thera Solutions
- 29 Nov 2023 Results published in the Bio-Thera Solutions Media Release.
- 29 Nov 2023 Primary endpoint has been met. (improvement from baseline in Psoriasis Area and Severity Index (PASI) score to Week 12), according to a Bio-Thera Solutions media release.
- 19 Jul 2023 Status changed from active, no longer recruiting to completed.